Skip to content

Author

K. Rohrberg

We have 5 of 139 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors.

PURPOSE To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in solid cancer patients. EXPERIMENTAL DESIGN Preclinical modeling in syngeneic t...

I. Teige, K. Rohrberg, A. Carneiro et al. · 0 citations
Open access Aug 2026

A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden

Abstract Purpose: The Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy (TEMPLE) study was a phase Ib/II trial evaluating the safety, tolerability, and efficacy of atezolizumab combined with thiopurine therapy in patients with metastatic solid tumors, aiming to increase tumor mutational burden (TMB) through sing...

C. F. Secher, M. Højgaard, I. Spanggaard et al. · 0 citations
Open access Aug 2026

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

The evidence of clinical efficacy in a pretreated population, favorable tolerability and low rate of treatment discontinuation observed in Parts A and B support further evaluation of rilvegostomig in Parts C-E of the study, which assess safety and efficacy in CPI-naïve patients with nonsquamous and/or squamous NSCLC.

K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al. · 1 citation
Open access Sep 2026

Engineering human endogenous retrovirus-K for improving immunogenicity and broad cancer targeting

HERV-K (HML-2) is the most studied transcriptionally active endogenous retrovirus in human cancers, yet immune tolerance and incomplete mechanistic understanding have impeded its clinical use as an immunotherapy target. We hypothesized that rational engineering of the HERV-K envelope putative immunosuppressive do...

M. D. Müller, L. Neukirch, E. Ragonnaud et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.